Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Assets (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Non-Current Assets for 16 consecutive years, with $273.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 2.35% year-over-year to $273.7 million, compared with a TTM value of $1.1 billion through Dec 2025, down 3.66%, and an annual FY2025 reading of $273.7 million, down 2.35% over the prior year.
  • Non-Current Assets was $273.7 million for Q4 2025 at Amicus Therapeutics, roughly flat from $274.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $308.3 million in Q4 2021 and bottomed at $273.7 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $294.3 million, with a median of $298.8 million recorded in 2022.
  • Peak annual rise in Non-Current Assets hit 0.41% in 2021, while the deepest fall reached 7.04% in 2021.
  • Year by year, Non-Current Assets stood at $308.3 million in 2021, then dropped by 2.58% to $300.4 million in 2022, then dropped by 1.84% to $294.8 million in 2023, then fell by 4.93% to $280.3 million in 2024, then fell by 2.35% to $273.7 million in 2025.
  • Business Quant data shows Non-Current Assets for FOLD at $273.7 million in Q4 2025, $274.7 million in Q3 2025, and $277.3 million in Q2 2025.